SCHEDULE: Baron Capital Discloses 5.93% Stake in CareDx

Baron Capital Group, Inc., Ronald Baron, and affiliated entities have reported a combined beneficial ownership of 5.93% in CareDx, Inc. common stock as of September 30, 2025.

Summary

• Baron Capital Group, Inc., Ronald Baron, BAMCO, Inc., and Baron Capital Management, Inc. have reported beneficial ownership of common stock in CAREDX, INC.
• As of September 30, 2025, Baron Capital Group, Inc. and Ronald Baron each beneficially own 3,155,180 shares.
• This represents 5.93% of CAREDX, INC.'s common stock.
• BAMCO, Inc. beneficially owns 2,721,072 shares, representing 5.11% of the class.
• Baron Capital Management, Inc. beneficially owns 434,108 shares, representing 0.81% of the class.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• BAMCO and Baron Capital Management, Inc. are subsidiaries of Baron Capital Group, Inc., and Ronald Baron owns a controlling interest in Baron Capital Group, Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership by a reputable investment firm like Baron Capital Group is generally viewed positively, as it signals institutional confidence in the issuer.

Positives

• Significant institutional investment from Baron Capital Group, a well-known investment firm, indicates confidence in CareDx's long-term prospects.
• A 5.93% stake suggests a material commitment to the company by a prominent institutional investor.

Industry Context

This filing indicates a significant institutional investor, Baron Capital Group, has taken a substantial position in CareDx, Inc. Such disclosures are common for publicly traded companies and can signal investor confidence or strategic interest in the biotechnology or diagnostics sector, where CareDx operates.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Baron Capital Group may instill greater confidence among existing and potential shareholders, potentially influencing stock valuation positively. It signals that a professional investment firm sees value in CareDx.

Key Dates

Recommendation

The filing indicates a significant vote of confidence from a prominent institutional investor, Baron Capital Group, which has acquired a 5.93% stake in CareDx. This suggests a belief in the company's long-term value. However, a Schedule 13G is purely an ownership disclosure and does not provide details on the company's operational performance, financial health, or future prospects. Therefore, while the institutional interest is a positive signal, a 'hold' recommendation is appropriate for existing investors, encouraging them to maintain their position while awaiting further fundamental updates. New investors should conduct further due diligence beyond this ownership disclosure.

Keywords

CareDx, CDNA, Baron Capital, Ronald Baron, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser, Holding Company